Abstract
This review summarizes current knowledge about glycated albumin. We review the changes induced by glycation on the properties of albumin, the pathological implications of high glycated albumin levels, glycated albumin quantification methods, and the use of glycated albumin as a complementary biomarker for diabetes mellitus diagnosis and monitoring and for dealing with long-term complications. The advantages and limits of this biomarker in different clinical settings are also discussed.
Similar content being viewed by others
References
J. Theodore Peters, All about Albumin. Academic Press, (1995)
P.J. Thornalley, A. Langborg, H.S. Minhas, Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344(Pt 1), 109–116 (1999)
K.J. Kim, B.W. Lee, The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab. J. 36(2), 98–107 (2012). doi:10.4093/dmj.2012.36.2.98
F.N. Ziyadeh, D.C. Han, J.A. Cohen, J. Guo, M.P. Cohen, Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system. Kidney Int. 53(3), 631–638 (1998)
S.L. Jeffcoate, Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet. Med. 21(7), 657–665 (2004)
J.W. Hartog, A.A. Voors, S.J. Bakker, A.J. Smit, D.J. van Veldhuisen, Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur. J. Heart Fail 9(12), 1146–1155 (2007)
X.M. He, D.C. Carter, Atomic structure and chemistry of human serum albumin. Nature 358(6383), 209–215 (1992)
K. Oettl, R.E. Stauber, Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br. J. Pharmacol. 151(5), 580–590 (2007)
G. Sudlow, D.J. Birkett, D.N. Wade, The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 11(6), 824–832 (1975)
U. Kragh-Hansen, V.T. Chuang, M. Otagiri, Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 25(6), 695–704 (2002)
M. Otagiri, A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab. Pharmacokinet. 20(5), 309–323 (2005)
J.R. Simard, P.A. Zunszain, C.E. Ha, J.S. Yang, N.V. Bhagavan, I. Petitpas, S. Curry, J.A. Hamilton, Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc. Natl. Acad. Sci. USA 102(50), 17958–17963 (2005)
J.E. Eom, E. Lee, K.H. Jeon, J. Sim, M. Suh, G.J. Jhon, Y. Kwon, Development of an albumin copper binding (ACuB) assay to detect ischemia modified albumin. Anal. Sci. 30(10), 985–990 (2014)
J. Masuoka, P. Saltman, Zinc(II) and copper(II) binding to serum albumin. A comparative study of dog, bovine, and human albumin. J. Biol. Chem. 269(41), 25557–25561 (1994)
A. Loban, R. Kime, H. Powers, Iron-binding antioxidant potential of plasma albumin. Clin. Sci. (Lond.) 93(5), 445–451 (1997)
S. Curry, H. Mandelkow, P. Brick, N. Franks, Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 5(9), 827–835 (1998)
S.J. Cho, G. Roman, F. Yeboah, Y. Konishi, The road to advanced glycation end products: a mechanistic perspective. Curr. Med. Chem. 14(15), 1653–1671 (2007)
F. Monacelli, D. Storace, C. D’Arrigo, R. Sanguineti, R. Borghi, D. Pacini, A.L. Furfaro, M.A. Pronzato, P. Odetti, N. Traverso, Structural alterations of human serum albumin caused by glycative and oxidative stressors revealed by circular dichroism analysis. Int. J. Mol. Sci. 14(6), 10694–10709 (2013)
J. Baraka-Vidot, C. Planesse, O. Meilhac, V. Militello, J. van den Elsen, E. Bourdon, P. Rondeau, Glycation alters ligand binding, enzymatic, and pharmacological properties of human albumin. Biochemistry 54(19), 3051–3062 (2015)
J.F. Day, S.R. Thorpe, J.W. Baynes, Nonenzymatically glucosylated albumin. In vitro preparation and isolation from normal human serum. J. Biol. Chem. 254(3), 595–597 (1979)
N. Iberg, R. Fluckiger, Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J. Biol. Chem. 261(29), 13542–13545 (1986)
H. Zoellner, J.Y. Hou, T. Hochgrebe, A. Poljak, M.W. Duncan, J. Golding, T. Henderson, G. Lynch, Fluorometric and mass spectrometric analysis of nonenzymatic glycosylated albumin. Biochem. Biophys. Res. Commun. 284(1), 83–89 (2001)
A. Frolov, R. Hoffmann, Identification and relative quantification of specific glycation sites in human serum albumin. Anal. Bioanal. Chem. 397(6), 2349–2356 (2010)
O.S. Barnaby, R.L. Cerny, W. Clarke, D.S. Hage, Quantitative analysis of glycation patterns in human serum albumin using 16O/18O-labeling and MALDI-TOF MS. Clin. Chim. Acta 412(17-18), 1606–1615 (2011)
S. Awasthi, N.A. Murugan, N.T. Saraswathi, Advanced glycation end products modulate structure and drug binding properties of albumin. Mol. Pharm. 12(9), 3312–3322 (2015)
F.L. Brancia, J.Z. Bereszczak, A. Lapolla, D. Fedele, L. Baccarin, R. Seraglia, P. Traldi, Comprehensive analysis of glycated human serum albumin tryptic peptides by off-line liquid chromatography followed by MALDI analysis on a time-of-flight/curved field reflectron tandem mass spectrometer. J. Mass Spectrom. 41(9), 1179–1185 (2006)
C. Wa, R.L. Cerny, W.A. Clarke, D.S. Hage, Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chim. Acta 385(1-2), 48–60 (2007)
O.S. Barnaby, R.L. Cerny, W. Clarke, D.S. Hage, Comparison of modification sites formed on human serum albumin at various stages of glycation. Clin. Chim. Acta 412(3-4), 277–285 (2011)
A. Barzegar, A.A. Moosavi-Movahedi, N. Sattarahmady, M.A. Hosseinpour-Faizi, M. Aminbakhsh, F. Ahmad, A.A. Saboury, M.R. Ganjali, P. Norouzi, Spectroscopic studies of the effects of glycation of human serum albumin on L-Trp binding. Protein Pept. Lett. 14(1), 13–18 (2007)
R. Kisugi, T. Kouzuma, T. Yamamoto, S. Akizuki, H. Miyamoto, Y. Someya, J. Yokoyama, I. Abe, N. Hirai, A. Ohnishi, Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin. Chim. Acta 382(1-2), 59–64 (2007)
K.S. Joseph, A.C. Moser, S.B. Basiaga, J.E. Schiel, D.S. Hage, Evaluation of alternatives to warfarin as probes for Sudlow site I of human serum albumin: characterization by high-performance affinity chromatography. J. Chromatogr. A 1216(16), 3492–3500 (2009)
K.S. Joseph, D.S. Hage, The effects of glycation on the binding of human serum albumin to warfarin and L-tryptophan. J. Pharm. Biomed. Anal. 53(3), 811–818 (2010)
J. Baraka-Vidot, A. Guerin-Dubourg, E. Bourdon, P. Rondeau, Impaired drug-binding capacities of in vitro and in vivo glycated albumin. Biochimie 94(9), 1960–1967 (2012)
R. Matsuda, J. Anguizola, K.S. Joseph, D.S. Hage, Analysis of drug interactions with modified proteins by high-performance affinity chromatography: binding of glibenclamide to normal and glycated human serum albumin. J. Chromatogr. A 1265, 114–122 (2012)
J. Anguizola, R. Matsuda, O.S. Barnaby, K.S. Hoy, C. Wa, E. DeBolt, M. Koke, D.S. Hage, Review: glycation of human serum albumin. Clin. Chim. Acta 425, 64–76 (2013)
F.N. Ziyadeh, M.P. Cohen, Effects of glycated albumin on mesangial cells: evidence for a role in diabetic nephropathy. Mol. Cell. Biochem. 125(1), 19–25 (1993)
S. Chen, M.P. Cohen, F.N. Ziyadeh, Amadori-glycated albumin in diabetic nephropathy: pathophysiologic connections. Kidney Int. Suppl. 77, S40–S44 (2000)
C. Jin, L. Lu, R.Y. Zhang, Q. Zhang, F.H. Ding, Q.J. Chen, W.F. Shen, Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus. Clin. Chim. Acta 408(1-2), 45–49 (2009)
D.A. Rubenstein, Z. Maria, W. Yin, Glycated albumin modulates endothelial cell thrombogenic and inflammatory responses. J. Diabetes Sci. Technol. 5(3), 703–713 (2011)
D. Blache, E. Bourdon, P. Salloignon, G. Lucchi, P. Ducoroy, J.M. Petit, B. Verges, L. Lagrost, Glycated albumin with loss of fatty acid binding capacity contributes to enhanced arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes. Diabetes 64(3), 960–972 (2015)
A. Bierhaus, P.M. Humpert, M. Morcos, T. Wendt, T. Chavakis, B. Arnold, D.M. Stern, P.P. Nawroth, Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. (Berl.) 83(11), 876–886 (2005)
A. Stirban, T. Gawlowski, M. Roden, Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Mol. Metab. 3(2), 94–108 (2014)
E. Shim, J.P. Babu, Glycated albumin produced in diabetic hyperglycemia promotes monocyte secretion of inflammatory cytokines and bacterial adherence to epithelial cells. J. Periodontal. Res. 50(2), 197–204 (2015)
C. Miele, A. Riboulet, M.A. Maitan, F. Oriente, C. Romano, P. Formisano, J. Giudicelli, F. Beguinot, E. Van Obberghen, Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism. J. Biol. Chem. 278(48), 47376–47387 (2003)
K. Shima, N. Ito, F. Abe, M. Hirota, M. Yano, Y. Yamamoto, T. Uchida, K. Noguchi, High-performance liquid chromatographic assay of serum glycated albumin. Diabetologia 31(8), 627–631 (1988)
K. Yasukawa, F. Abe, N. Shida, Y. Koizumi, T. Uchida, K. Noguchi, K. Shima, High-performance affinity chromatography system for the rapid, efficient assay of glycated albumin. J. Chromatogr. 597(1-2), 271–275 (1992)
T. Kouzuma, T. Usami, M. Yamakoshi, M. Takahashi, S. Imamura, An enzymatic method for the measurement of glycated albumin in biological samples. Clin. Chim. Acta 324(1-2), 61–71 (2002)
T. Kohzuma, T. Yamamoto, Y. Uematsu, Z.K. Shihabi, B.I. Freedman, Basic performance of an enzymatic method for glycated albumin and reference range determination. J. Diabetes Sci. Technol. 5(6), 1455–1462 (2011)
Takei, I., Hoshino, T., Tominaga, M., Ishibashi, M., Kuwa, K., Umemoto, M., Tani, W., Okahashi, M., Yasukawa, K., Kohzuma, T., Sato, A.: Committee on diabetes mellitus indices of the Japan society of clinical chemistry-recommended reference measurement procedure and reference materials for glycated albumin determination. Ann. Clin. Biochem. (2015)
T. Shafi, S.M. Sozio, L.C. Plantinga, B.G. Jaar, E.T. Kim, R.S. Parekh, M.W. Steffes, N.R. Powe, J. Coresh, E. Selvin, Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care 36(6), 1522–1533 (2013)
E.D. Schleicher, R. Mayer, E.M. Wagner, K.D. Gerbitz, Is serum fructosamine assay specific for determination of glycated serum protein? Clin. Chem. 34(2), 320–323 (1988)
K. Rodriguez-Capote, K. Tovell, D. Holmes, J. Dayton, T.N. Higgins, Analytical evaluation of the diazyme glycated serum protein assay on the siemens ADVIA 1800: comparison of results against HbA1c for diagnosis and management of diabetes. J. Diabetes Sci. Technol. 9(2), 192–199 (2015)
S. Takahashi, H. Uchino, T. Shimizu, A. Kanazawa, Y. Tamura, K. Sakai, H. Watada, T. Hirose, R. Kawamori, Y. Tanaka, Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr. J. 54(1), 139–144 (2007)
N. Furusyo, T. Koga, M. Ai, S. Otokozawa, T. Kohzuma, H. Ikezaki, E.J. Schaefer, J. Hayashi, Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia 54(12), 3028–3036 (2011)
H. Ikezaki, N. Furusyo, T. Ihara, T. Hayashi, K. Ura, S. Hiramine, F. Mitsumoto, K. Takayama, M. Murata, T. Kohzuma, M. Ai, E.J. Schaefer, J. Hayashi, Glycated albumin as a diagnostic tool for diabetes in a general Japanese population. Metabolism 64(6), 698–705 (2015)
P. Gram-Hansen, J. Eriksen, T. Mourits-Andersen, L. Olesen, Glycosylated haemoglobin (HbA1c) in iron- and vitamin B12 deficiency. J. Intern. Med. 227(2), 133–136 (1990)
E. Coban, M. Ozdogan, A. Timuragaoglu, Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol. 112(3), 126–128 (2004)
C. Kim, K.M. Bullard, W.H. Herman, G.L. Beckles, Association between iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 33(4), 780–785 (2010)
D. Church, D. Simmons, More evidence of the problems of using HbA1c for diagnosing diabetes? The known knowns, the known unknowns and the unknown unknowns. J. Intern. Med. 276(2), 171–173 (2014)
R.M. Cohen, R.S. Franco, P.K. Khera, E.P. Smith, C.J. Lindsell, P.J. Ciraolo, M.B. Palascak, C.H. Joiner, Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 112(10), 4284–4291 (2008)
M. Koga, H. Saito, M. Mukai, S. Matsumoto, S. Kasayama, Influence of iron metabolism indices on glycated haemoglobin but not glycated albumin levels in premenopausal women. Acta Diabetol. 47(Suppl 1), 65–69 (2010)
C. Krzisnik, J. Lukac-Bajalo, Glycosylated hemoglobin in fractions of erythrocytes of different ages. J. Endocrinol. Invest. 16(7), 495–498 (1993)
M.S. Radin, Pitfalls in hemoglobin A1c measurement: when results may be misleading. J. Gen. Intern. Med. 29(2), 388–394 (2014)
R.L. Phelps, G.R. Honig, D. Green, B.E. Metzger, M.C. Frederiksen, N. Freinkel, Biphasic changes in hemoglobin A1c concentrations during normal human pregnancy. Am. J. Obstet. Gynecol. 147(6), 651–653 (1983)
K. Hashimoto, S. Noguchi, Y. Morimoto, S. Hamada, K. Wasada, S. Imai, Y. Murata, S. Kasayama, M. Koga, A1C but not serum glycated albumin is elevated in late pregnancy owing to iron deficiency. Diabetes Care 31(10), 1945–1948 (2008)
K. Hashimoto, T. Osugi, S. Noguchi, Y. Morimoto, K. Wasada, S. Imai, M. Waguri, R. Toyoda, T. Fujita, S. Kasayama, M. Koga, A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women. Diabetes Care 33(3), 509–511 (2010)
S. Suzuki, M. Koga, S. Amamiya, A. Nakao, K. Wada, K. Okuhara, S. Hayano, A.R. Sarhat, H. Takahashi, K. Matsuo, Y. Tanahashi, K. Fujieda, Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia 54(9), 2247–2253 (2011)
B.I. Freedman, R.N. Shenoy, J.A. Planer, K.D. Clay, Z.K. Shihabi, J.M. Burkart, C.Y. Cardona, L. Andries, T.P. Peacock, H. Sabio, J.R. Byers, G.B. Russell, A.J. Bleyer, Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit. Dial. Int. 30(1), 72–79 (2010)
B.I. Freedman, Z.K. Shihabi, L. Andries, C.Y. Cardona, T.P. Peacock, J.R. Byers, G.B. Russell, R.J. Stratta, A.J. Bleyer, Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am. J. Nephrol. 31(5), 375–379 (2010)
A.E. Sumner, M.T. Duong, P.C. Aldana, M. Ricks, M.K. Tulloch-Reid, J.N. Lozier, S.T. Chung, D.B. Sacks, A1C combined with glycated albumin improves detection of prediabetes in Africans: the Africans in America study. Diabetes Care 39(2), 271–277 (2016)
M. Alssema, H.M. Boers, A. Ceriello, E.S. Kilpatrick, D.J. Mela, M.G. Priebe, P. Schrauwen, B.H. Wolffenbuttel, A.F. Pfeiffer, Diet and glycaemia: the markers and their meaning. A report of the Unilever Nutrition Workshop. Br. J. Nutr. 113(2), 239–248 (2015)
K. Noda, B. Zhang, A. Iwata, H. Nishikawa, M. Ogawa, T. Nomiyama, S. Miura, H. Sako, K. Matsuo, E. Yahiro, T. Yanase, K. Saku, Lifestyle changes through the use of delivered meals and dietary counseling in a single-blind study. The STYLIST study. Circ. J. 76(6), 1335–1344 (2015)
J. Murai, S. Soga, H. Saito, M. Koga, Usefulness of glycated albumin for early detection of deterioration of glycemic control state after discharge from educational admission. Endocr. J. 60(4), 409–413 (2013)
M. Koga, J. Murai, H. Saito, S. Kasayama, A. Imagawa, T. Hanafusa, T. Kobayashi, Serum glycated albumin to haemoglobin A(1C) ratio can distinguish fulminant type 1 diabetes mellitus from type 2 diabetes mellitus. Ann. Clin. Biochem. 47(Pt 4), 313–317 (2010)
Y. Ueda, H. Matsumoto, Recent topics in chemical and clinical research on glycated albumin. J. Diabetes Sci. Technol. 9(2), 177–182 (2015)
M. Tominaga, H. Eguchi, H. Manaka, K. Igarashi, T. Kato, A. Sekikawa, Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22(6), 920–924 (1999)
The DECODE study group. European Diabetes Epidemiology Group, Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 354(9179), 617–621 (1999)
R.J. Heine, B. Balkau, A. Ceriello, S. Del Prato, E.S. Horton, M.R. Taskinen, What does postprandial hyperglycaemia mean? Diabet. Med. 21(3), 208–213 (2004)
K. Yoshiuchi, M. Matsuhisa, N. Katakami, Y. Nakatani, K. Sakamoto, T. Matsuoka, Y. Umayahara, K. Kosugi, H. Kaneto, Y. Yamasaki, M. Hori, Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr. J. 55(3), 503–507 (2008)
M. Koga, J. Murai, H. Saito, S. Kasayama, Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care 33(2), 270–272 (2010)
M. Koga, J. Murai, H. Saito, M. Mukai, S. Matsumoto, S. Kasayama, Glycated albumin levels are higher relative to glycated haemoglobin levels in gastrectomized subjects. Ann. Clin. Biochem. 47(Pt 1), 39–43 (2010)
E. Selvin, A.M. Rawlings, M. Grams, R. Klein, A.R. Sharrett, M. Steffes, J. Coresh, Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes Endocrinol. 2(4), 279–288 (2014)
D.M. Nathan, P. McGee, M.W. Steffes, J.M. Lachin, D.E.R. Group, Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes 63(1), 282–290 (2014)
N. Furusyo, T. Koga, M. Ai, S. Otokozawa, T. Kohzuma, H. Ikezaki, E.J. Schaefer, J. Hayashi, Plasma glycated albumin level and atherosclerosis: results from the Kyushu and Okinawa Population Study (KOPS). Int. J. Cardiol. 167(5), 2066–2072 (2013)
X. Ma, Y. Shen, X. Hu, Y. Hao, Y. Luo, J. Tang, J. Zhou, Y. Bao, W. Jia, Associations of glycated haemoglobin A1c and glycated albumin with subclinical atherosclerosis in middle-aged and elderly Chinese population with impaired glucose regulation. Clin. Exp. Pharmacol. Physiol. 42(6), 582–587 (2015)
M. Inaba, S. Okuno, Y. Kumeda, S. Yamada, Y. Imanishi, T. Tabata, M. Okamura, S. Okada, T. Yamakawa, E. Ishimura, Y. Nishizawa, C.K.D.E.R.G. Osaka, Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J. Am. Soc. Nephrol. 18(3), 896–903 (2007)
M. Koga, J. Murai, H. Saito, S. Matsumoto, S. Kasayama, Effects of thyroid hormone on serum glycated albumin levels: study on non-diabetic subjects. Diabetes Res. Clin. Pract. 84(2), 163–167 (2009)
R. Nishimura, A. Kanda, H. Sano, T. Matsudaira, Y. Miyashita, A. Morimoto, T. Shirasawa, T. Kawaguchi, N. Tajima, Glycated albumin is low in obese, non-diabetic children. Diabetes Res. Clin. Pract. 71(3), 334–338 (2006)
M. Koga, M. Otsuki, S. Matsumoto, H. Saito, M. Mukai, S. Kasayama, Negative association of obesity and its related chronic inflammation with serum glycated albumin but not glycated hemoglobin levels. Clin. Chim. Acta 378(1-2), 48–52 (2007)
M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, Serum glycated albumin, but not glycated haemoglobin, is low in relation to glycemia in hyperuricemic men. Acta Diabetol. 47(2), 173–177 (2010)
M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, Serum glycated albumin, but not glycated hemoglobin, is low in relation to glycemia in men with hypertriglyceridemia. J. Diabetes Investig. 1(5), 202–207 (2010)
M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, Serum glycated albumin levels, but not glycated hemoglobin, is low in relation to glycemia in non-diabetic men with nonalcoholic fatty liver disease with high alanine aminotransferase levels. Clin. Biochem. 43(12), 1023–1025 (2010)
T. Trenti, A. Cristani, G. Cioni, R. Pentore, C. Mussini, E. Ventura, Fructosamine and glycated hemoglobin as indices of glycemic control in patients with liver cirrhosis. Ric. Clin. Lab. 20(4), 261–267 (1990)
M. Koga, S. Kasayama, H. Kanehara, Y. Bando, CLD (chronic liver diseases)-HbA1C as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. Diabetes Res. Clin. Pract. 81(2), 258–262 (2008)
Y. Bando, H. Kanehara, D. Toya, N. Tanaka, S. Kasayama, M. Koga, Association of serum glycated albumin to haemoglobin A1C ratio with hepatic function tests in patients with chronic liver disease. Ann. Clin. Biochem. 46(Pt 5), 368–372 (2009)
T. Araki, Y. Ishikawa, H. Okazaki, Y. Tani, S. Toyooka, M. Satake, U. Miwa, K. Tadokoro, Introduction of glycated albumin measurement for all blood donors and the prevalence of a high glycated albumin level in Japan. J. Diabetes Investig. 3(6), 492–497 (2012)
M. Ai, S. Otokozawa, E.J. Schaefer, B.F. Asztalos, K. Nakajima, P. Shrader, S. Kathiresan, J.B. Meigs, G. Williams, D.M. Nathan, Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. Clin. Chim. Acta 406(1-2), 71–74 (2009)
ADA, Standards of medical care in diabetes-2015: summary of revisions. Diabetes Care 38(Suppl), S4 (2015)
American Diabetes, A, Standards of medical care in diabetes-2015 abridged for primary care providers. Clin. Diabetes 33(2), 97–111 (2015)
Acknowledgments
We thank Ms Judith Baggott for English-language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Dozio, E., Di Gaetano, N., Findeisen, P. et al. Glycated albumin: from biochemistry and laboratory medicine to clinical practice. Endocrine 55, 682–690 (2017). https://doi.org/10.1007/s12020-016-1091-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-1091-6